Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the Southeastern Section of the American Urological Association
Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in patients with Peyronie's disease (PD) ...
Endo Reschedules Release of Fourth Quarter and Full Year 2024 Earnings Results and Conference Call
Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it has rescheduled the release of its fourth quarter and full year 2024 financial results to March 13, 2025, prior to market ...
FiercePharma16d
Endo highlights a Xiaflex success story in first branded commercial for Dupuytren's contracture treatment
More than a decade after earning FDA approval for Xiaflex as a nonsurgical treatment option for Dupuytren’s contracture, Endo is debuting its first-ever branded TV commercial in the indication.
The Victoria Advocate26d
Endo Launches "Steve's Journey," the First Branded Dupuytren's Contracture Commercial for XIAFLEX® (collagenase clostridium histolyticum)
Campaign builds on the momentum of Endo's disease awareness efforts.Commercial features a real patient—who was an untreated patient in a prior Endo video series—and his wife, ...